Table 2 Patient and tumor characteristics

Gender

Male

30 (55)

22 (63)

Female

25 (45)

13 (37)

Age

Mean

61

61

SD

10.5

9.4

Range

53–69

51–69

Primary tumor present at baseline

16 (29)

12 (34)

ECOG PS

0 vs 1

55 (100)

35 (100)

Stage at initial diagnosis

I

1 (2)

1 (3)

II

2 (4)

0

III

12 (22)

8 (23)

IV

40 (73)

26 (74)

Number of site (s) involved

1

12 (22)

8 (23)

2

20 (36)

15 (43)

>2

23 (42)

12 (34)

Fluoropyrimidines

55 (100)

35 (100)

Oxaliplatin

53 (96)

35 (100)

Irinotecan

55 (100)

35 (100)

VEGF inhibitors^a

53 (96)

34 (97)

EGFR inhibitors^b

27 (49)

20 (57)